Home / Business and Economy / Pharma Investment: True North Backs Embio Ltd
Pharma Investment: True North Backs Embio Ltd
27 May
Summary
- True North invests $50 million for a 25% stake in Embio Ltd.
- Embio Ltd is a manufacturer of complex APIs and intermediates.
- Investment will fund R&D and capacity expansion in Gujarat.
True North, a prominent private equity firm, has invested in Embio Ltd, a manufacturer focused on Active Pharmaceutical Ingredients (APIs) for regulated markets. This strategic investment of approximately $50 million secures a 25% stake for True North, marking its first foray into the pharmaceutical sector with its Fund VII.
The infusion of capital is earmarked for crucial growth initiatives. Embio plans to channel these funds into robust research and development efforts. Additionally, the investment will support capacity expansion at its upcoming manufacturing facility located in Dahej, Gujarat.
Embio Ltd distinguishes itself as a producer of complex APIs and intermediates, leveraging deep expertise in synthetic biology. The company integrates both chemical and fermentation-based processes, alongside specialized knowledge in controlled substances. This technological prowess allows Embio to serve a diverse therapeutic range.
The company boasts a global reach, supplying its products to customers in over 80 markets. Key regions include the United States, Europe, Japan, Brazil, Canada, Africa, and the Middle East. True North's partnership is expected to further strengthen Embio's position in regulated markets.
